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Baﬁlomycinnﬂicting data have been reported regarding several aspects of vaccinia virus (VV)
entry. To address this, we used a β-galactosidase reporter virus to monitor virus entry into multiple cell types
under varying conditions. Entry into HeLa, B78H1 and L cells was strongly inhibited by heparin whereas
entry into Vero and BSC-1 cells was unaffected. Baﬁlomycin also exhibited variable and cell-type-speciﬁc
effects on VV entry. Entry into B78H1 and BSC-1 cells was strongly inhibited by baﬁlomycin whereas entry
into Vero and HeLa cells was only partially inhibited suggesting the co-existence of both pH-dependent and
pH-independent VV entry pathways in these cell types. Finally, entry into HeLa, B78H1, L and BSC-1 cells
exhibited a lag of 6–9 min whereas this delay was undetectable in Vero cells. Our results suggest that VV
exploits multiple cell attachment and entry pathways allowing it to infect a broad range of cells.
© 2009 Elsevier Inc. All rights reserved.IntroductionVaccinia virus (VV) is the prototypical member of the orthopox-
virus genus (Moss, 2001) and shares a high degree of DNA sequence
similarity and gene conservation with the human pathogen, variola
virus (Gubser et al., 2004). Because of its extensive antigenic similarity
to variola and its relatively low pathogenic potential, VV was used
with great success as a vaccine against variola. Although variola was
eradicated from the global human population some 30 years ago,
there remains considerable concern regarding the possible re-
introduction of variola virus as an act of bioterrorism (Mayr, 2003).
Two forms of enveloped infectious virus particles are produced in
cells infected with VV (Appleyard et al., 1971), the mature virus (MV)
and the enveloped virus (EV). MV forms within the infected cell and
are released upon cell lysis. EV begins as MV particles, but go on to
acquire an additional, trans-Golgi-derived envelope prior to being
delivered to the host cell surface (Moss, 2001). Importantly, EV and
MV contain distinct subsets of viral proteins in their outer envelopes
(Appleyard et al., 1971; Moss, 2006) and thus present different targets
to the host cell as well as to the host immune system. Several
hypotheses have been proposed regarding the entry pathways of
these two infectious forms. Because signiﬁcantly less EV is produced
in infected cells and its outer membrane is relatively fragile (Ichihashi,
1996), this form of the virus has proven more difﬁcult to purify. For
this reason, most studies of vaccinia virus entry have focused on MV.40th Street School of Dental
104, USA.
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l rights reserved.Studies on the role of cell-surface glycosaminoglycans (GAGs) in
MV attachment and entry have been reported by a number of
laboratories. Chung et al. (1998) ﬁrst reported the ability of puriﬁed
VVvirions to bind heparin suggesting a role for heparan sulfate binding
in virus infection. To date, two MV proteins, A27 and H3, have been
reported to bind cell-surface heparan sulfate (Chung et al., 1998; Lin et
al., 2000). A third MV protein, D8, has been reported to bind another
abundant cell-surface GAG, chondroitin sulfate (Hsiao et al., 1999). The
importance of heparin sulfate for virus infection is highlighted by the
observation that soluble heparin reduces virus attachment and entry
(Carter et al., 2005; Chunget al.,1998). Second, soluble forms of A27, D8
and H3 bind to cells and block virus attachment and infection (Chung
et al.,1998; Ho et al., 2005;Hsiao et al.,1998,1999; Lai et al.,1990; Lin et
al., 2000; Maa et al., 1990). Third, cells lacking sulfated GAGs are more
resistant to VV infection (Chung et al.,1998; Hsiao et al.,1999; Lin et al.,
2000). Additionally, antibodies raised against each of these proteins
blocks VV infection (Hsiao et al., 1999; Lin et al., 2000), although this
effect was not shown to be entirely attributable to interference with
cell-surface GAG interactions.
Numerous studies have also addressed the role(s) of endocytosis
and low pH in VV entry. The earliest electronmicroscopic (EM) studies
revealed the appearance of enveloped MV particles within vesicles
inside L cells suggesting that VV entered cells via an endocytic route
(Dales and Siminovitch, 1961; Dales and Kajioka, 1964). Subsequent
EM studies of MV entry into HeLa and L cells revealed direct fusion of
the virion envelope with the host cell plasma membrane (Armstrong
et al., 1973; Chang and Metz, 1976). The authors suggested that if
endocytic entry does occur, it is not the major route of virus entry.
More recently, biochemical data have provided evidence for entry by
Fig. 1. β-galactosidase expression following infection by the vaccinia reporter virus,
vSIJC-20. Cells were inoculated at 37 °C and maintained at this temperature for the
duration of the infection. (A) B78H1, BSC-1, HeLa and Vero cells were infected with
vSIJC-20 at a multiplicity of 1 pfu/cell for various times prior to assaying β-galactosidase
activity. Enzyme activity present in cells infected for 0 h was subtracted from the
activity measured in cells infected for 2, 4 or 6 h. Inset: Expanded scale showing β-
galactosidase activity at 2 h post-infection. (B) β-galactosidase activity induced in B78-
H1, BSC-1, HeLa and Vero cells infected with vSIJC-20 for 6 h at the indicated
multiplicities of infection (pfu/cell).
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showed that the lysosomotropic agents, methylamine and chloro-
quine had no effect on VV entry into BSC-40 cells suggesting a pH-
independent entry mechanism. Consistent with this, reports by Doms
et al. (1990), Ichihashi (1996) and Vanderplasschen et al. (1998)
showed that lysosomotropic agents also failed to diminish MV entry
into BSC-1, Vero and RK13 cells, respectively. Furthermore, both Doms
et al. (1990) and Ichihashi (1996) reported that low pH treatment of
MV did not enhance membrane fusion or entry activity providing
further support for a pH-independent entry mechanism. In contrast to
the largely consonant earlier biochemical data, it was reported by
Townsley et al. (2006) that inhibitors of endosomal acidiﬁcation, such
as baﬁlomycin A1 and concanamycin A, signiﬁcantly diminished MV
entry into BSC-1, RK13 and HuTK-cells. These authors concluded that
MV entry is, in fact dependent upon low pH. Even more recently, it
was reported that in at least one cell type (BSC40) vaccinia virus
appears to enter via macropinocytosis (Mercer and Helenius, 2008).
Although the origin and natural host species of VV are unknown
(Moss, 2001), it infects a variety of cell types from awide range of host
species. The apparently conﬂicting results obtained in previous
studies of virus entry prompted us to consider the possibility that
VV entry is cell-type-dependent. To test this, we examined several
aspects of virus entry using a variety of host cells. For the purposes of
this study, we deﬁne entry as the early events in virus infection that
culminate in the introduction of a virion core into the cytoplasm of a
host cell. Thus, we consider attachment, receptor binding, endocy-
tosis, membrane fusion and core uncoating to be steps in the entry
process. To facilitate these studies, we developed an entry assay based
on β-galactosidase expression from a reporter virus. We validated this
entry assay by showing that similar results were obtained using
plaque-reduction and core-uncoating assays. Our results show the
importance of cell surface HSPG and the need for low endosomal pH,
vary considerably depending upon the cell type used by the virus.
Results
Synthesis of β-galactosidase in VV reporter-virus-infected cells
Various methods of measuring VV entry have been reported.
Although the classical method of plaque formation has been widely
used, it may not always be the best way of measuring virus entry per
se as a number of downstream events in virus replication must take
place in order for plaque formation to occur. Perhaps the most
sensitive method described to date for studying strictly entry is to
follow virus uncoating. In this assay, the viral core is detected within
the cytoplasm of a host cell using core-speciﬁc antibodies (Locker et
al., 2000; Vanderplasschen et al., 1998). However, because this assay
involves ﬂuorescence microscopy, data acquisition is tedious and is
not amenable to processing large sample numbers. Additionally, this
method does not readily lend itself to quantitative measurements of
entry. Increasingly, reporter viruses that express β-galactosidase, GFP
or ﬁreﬂy luciferase under the control of an early viral promoter have
been employed as rapid, sensitive and quantitative means of
measuring VV entry (Ho et al., 2005; Hsiao et al., 1998; Townsley et
al., 2006). To develop such an entry assay, we tested a recombinant VV
carrying β-galactosidase under the p7.5 early/late viral promoter.
Virus entry was indicated by the induction of β-galactosidase activity
following inoculation of various cell types in a 96-well plate. Fig. 1A
shows a typical time course of β-galactosidase expression in BSC-1,
B78H1, HeLa and Vero cells infected with the reporter virus using a
multiplicity of infection (MOI) of 1 pfu/cell. Although our virus stocks
are routinely titered on BSC-1 cells, we have observed that stock titers
vary by nomore than 2-fold on B78H1, Vero and HeLa cells. A low level
of β-galactosidase activity was detectable as early as 2 h post-infection
(inset) and enzyme activity increased thereafter in a time-dependent
manner in each cell type. To assess the amount of virus required toinduce readily detectable β-galactosidase activity, we infected cells for
6 h using various MOI. Here, β-galactosidase activity was detectable
following infection with as little as 0.1 pfu/cell. However, β-
galactosidase activities induced by 1 pfu/cell were somewhat more
reproducible. Therefore, with the goal of achieving a reasonable level
of sensitivity to inhibitors of virus entry while allowing reliable
detection in a relatively short period of time, we chose to carry out our
entry studies using a multiplicity of 1 pfu/cell and 6 h of infection.
Virus neutralization
As one way to establish the validity of the β-galactosidase reporter
virus assay for studies of VV entry, we performed a virus neutraliza-
tion experiment and compared the results with those of a standard
plaque reduction neutralization test (PRNT). We previously reported
the preparation of monoclonal and polyclonal antibodies to a
truncated form of the VV L1 protein (Aldaz-Carroll et al., 2005b).
Many of these anti-L1 antibodies exhibited strong MV-neutralizing
activity in a PRNT. We tested several anti-L1 IgG's in parallel using a
PRNT as well as the β-galactosidase entry assay. A representative
neutralization assay using one of these antibodies (VMC-2) is shown
in Fig. 2. Both the PRNT (Fig. 2A) and the reporter virus entry assay
(Fig. 2B) resulted in nearly the same neutralization titers deﬁned as
the IgG concentration required to achieve a 50% reduction in virus
Fig. 2. Effect of a virus-neutralizing antibody on entry of vSIJC-20 asmeasured by plaque
reduction (Panel A) and β-galactosidase expression (Panel B). vSIJC-20 was incubated
with various concentrations of an anti-L1 monoclonal antibody (VMC-2) for 1 h at 37 °C.
Virus was then either plated on HeLa cells for plaque assay or in a 96-well plate for β-
galactosidase expression. An anti-myc monoclonal antibody was used as a control.
385J.C. Whitbeck et al. / Virology 385 (2009) 383–391entry (plaque number or β-galactosidase activity). Although data from
experiments using HeLa cells are shown, similar results were also
observed using BSC-1 cells (data not shown). As an additional
validation of the β-galactosidase reporter virus entry assay, we
examined the effect of VMC-2 on the appearance of uncoated VV
cores via immunoﬂuorescence microscopy (Fig. 3) similar to that ﬁrstFig. 3. Effects of an MV-neutralizing MAb and heparin on vaccinia virus core uncoating. H
infected and permeabilized (Panel B) or infected with MV that had been preincubated for 1 h.
at 37 °C, cells were ﬁxed, permeabilized with 0.1% saponin (Panels B – D only) and incuba
(green). To reveal cell contours, cell surface glycoproteins were stained with wheat germ agdescribed by Vanderplasschen et al. (1998). In this experiment,
puriﬁed vaccinia virus was mock-treated or pre-incubated with the
virus-neutralizing monoclonal antibody VMC-2 (Aldaz-Carroll et al.,
2005b) prior to infection of HeLa cells. After 90 min at 37 °C, uncoated
intracellular vaccinia virus cores were detected using a rabbit
polyclonal antiserum (R236) raised against 2 synthetic peptides
mimicking portions of the vaccinia virus A4 (p39) polypeptide. No
vaccinia virus cores were detected in infected, but non-permeabilized
cells (Fig. 3A). However, following permeabilization, numerous cores
were clearly visible in the cytoplasm of infected cells (Fig. 3B). When
virus was pre-incubated with a neutralizing monoclonal antibody
(Panel C), the appearance of intracellular cores was greatly diminished
indicating that VMC-2 had blocked infection at a step prior to virus
uncoating. Based on these results, we used the reporter virus assay to
examine other aspects of MV entry as well.
Inhibition of VV entry by heparin is cell-type dependent
VV carries at least two proteins capable of binding cell-surface
heparan sulfate (A27 and H3) and one protein that binds chondroitin
sulfate (D8). Many viruses utilize cell-surface GAGs as a means of
attachment to host cells (Marsh and Helenius, 2006; Olofsson and
Bergstrom, 2005). In such instances, virus attachment and, as a result,
entry can be inhibited to some extent by pre-incubation of virus with
heparin, heparan sulfate or chondroitin sulfate. Under these condi-
tions, heparin or soluble GAGs presumably bind to virions and
interfere with the attachment to GAGs on the host cell surface. VV
entry exhibits variable sensitivity to inhibition by soluble heparin
(Carter et al., 2005; Chung et al., 1998). The greatest reported effect of
soluble heparin occurred using BSC-40 cells wherein VV infectionwas
reduced by up to 60%. In contrast, heparin reduced virus infection of
HeLa cells by only 27% and had little or no effect on infection of BSC-1,
RK-13 and PtK-2 cells. Since these earlier data were obtained using a
plaque reduction assay, we questionedwhether soluble heparinmight
exhibit a different pattern of inhibition using the β-galactosidase
reporter virus entry assay. Similar to previously published results, we
found that VV entry into BSC-1 and Vero cells was only weakly
inhibited by the highest concentrations of heparin (Fig. 4A). In
contrast, virus entry into B78H1 and HeLa cells was reduced to a much
greater extent by heparin (40% and 70% inhibition, respectively). To
test the possibility that heparin might have affected post-entry events
(ie. early viral gene expression) we performed 2 additional experi-
ments. First, we examined the effect of adding heparin at 1 h post-
infection (Fig. 4B). If heparin had altered the ability of infected cells to
express β-galactosidase, we would expect to see a decrease in its
expression under these conditions. Instead, we found that addition of
heparin 1 h after infection had no effect on β-galactosidase activity,eLa cells on glass coverslips were infected with MV and non-permeabilized (Panel A),
at 37 °C with VMC-2MAb IgG (Panel C) or with heparin (Panel D). After 90min infection
ted with R236 anti-A4-peptide IgG. R236 staining was revealed using goat anti-rabbit
glutinin coupled to a red ﬂuorescent dye.
Fig. 4. Effect of heparin on vaccinia entry. vSIJC-20 was either mock-treated (Panel B) or incubated with various concentrations of soluble heparin for 1 h at 37 °C (Panels A and C).
Virus was then plated on BSC-1, Vero, B78H1 and HeLa cells (Panel A) or on sog9, BSC-1, gro2c and L cells (Panel C). After 1 h of infection, the inoculumwas removed and replacedwith
medium containing heparin. After 6 h of infection, cells were lysed and assayed for β-galactosidase expression. Results are plotted as a percentage of β-gal activity induced in the
absence of heparin. Panel D: L, gro2c and sog9 cells were incubated (at 4 °C) with various concentrations of puriﬁed MV for 1 h. Cells were washed and ﬁxed with 3%
paraformaldehyde. Bound virions were detected via indirect immunoperoxidase colorimetric assay.
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second means of verifying the point at which heparin inhibition of VV
infection occurs, we examined the effect of heparin on VV core
uncoating in HeLa cells by immunoﬂuorescence microscopy (Fig. 3D).
Here, the appearance of uncoated VV cores was markedly reduced
following pre-incubation of virus with heparin (100 μg/mL) indicating
that infection had been blocked at a step prior to virus penetration. In
a separate experiment, heparin also inhibited virus entry into L cells
(Fig. 4C) suggesting that HSPG play a role in VV attachment to these
cells as well. Gro2C and Sog9 are L cell derivatives deﬁcient in heparan
sulfate or heparan sulfate and chondroitin sulfate synthesis, respec-
tively (Banﬁeld et al., 1995; Gruenheid et al., 1993). Soluble heparin
showed a diminished ability to block VV infection of Gro2C cells and
had little effect on infection of Sog9 cells. These data suggest that in L
cells, both heparan sulfate as well as chondroitin sulfate play roles in
VV attachment as previously reported. Based on the studies shown
here, we conclude that HSPG are important for VV entry into some
cells (ie. HeLa, B78H1 and L), but are of lesser importance on others (ie.
BSC-1 and Vero). Although the GAG-binding proteins of MV (ie. A27,
H3 and D8) are commonly referred to as attachment factors, the
importance of GAGs for virion attachment to cells has never beendirectly assessed. To examine the effect of GAGs on the binding of MV's
to host cells, we used a cell-based ELISA (Fig. 4D) to detect virions
bound to cells. In this experiment, L, gro2c and sog9 cells were grown
in wells of a 96-well plate for 24 h. Cells were chilled (4 °C) to prevent
virus entry and various amounts of gradient-puriﬁed MV were added.
Unbound virions were then washed away and the remaining (cell-
bound)MVwere ﬁxed to the cell surface and detected using an anti-L1
monoclonal antibody. Interestingly, MV bound to gro2c and L cells
with similar efﬁciency, but bound much more weakly to sog9 cells.
Since gro2c cells lack HSPG, but sog9 cells lack both HSPG and
chondroitin sulfate proteoglycans (CSPG), these results support the
notion that CSPG can compensate for the absence of HSPG and allow
MV attachment.
VV entry into murine B78H1 cells is pH-dependent while entry into Vero
cells is pH independent
EM studies of MV entry have shown virus entering cells either by
direct fusion with the plasma membrane or by fusion with endocytic
vesicles. Studies using lysosomotropic agents have also led to
seemingly contradictory results. In light of recent studies showing
Fig. 5. Effect of baﬁlomycin on vaccinia virus entry. BSC-1, Vero, B78H1 and HeLa cells
were pre-incubated with the indicated concentrations of baﬁlomycin for 90 min
(Panel A) or mock-treated (Panel B). Cells were then infected with vSIJC-20 in the
presence (A) or absence (B) of baﬁlomycin. At 1 h post infection, the virus inoculumwas
removed and freshmedium containing baﬁlomycinwas added. Six hours post-infection,
the cells were lysed and assayed for β-galactosidase expression. Results are plotted as a
percentage of β-gal activity induced in the absence of baﬁlomycin.
Fig. 6. Inactivation of vaccinia virus following brief low-pH treatment. vSIJC-20 was
incubated for various times (from 1 to 8 min) in citrate-saline buffer at 37 °C. The pH of
the virus-containing samples was then rapidly neutralized by addition of an excess of
DMEM–HEPES (pH7). Virus was then plated on BSC-1 cells and incubated for 6 h. Cells
were then lysed and assayed for β-galactosidase expression.
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a cell-type-dependent manner, we asked whether there might be cell-
type differences in the pH-dependency of VV entry as well. To test for
pH-dependent entry of MV, we used baﬂomycin, a drug that inhibits
the endosomal Na/H+ pump and thereby prevents acidiﬁcation of the
endosomal compartment. The effects of baﬁlomycin on VV entry were
examined in several different cell lines. The data in Fig. 5A show that
baﬁlomycin inhibited virus entry to some extent in each of the cell
types tested. Entry into Vero cells was least sensitive to baﬁlomycin.
Interestingly, in these cells entry was reduced by about 35% at 25 nM,
but higher baﬁlomycin concentrations did not further reduce virus
entry suggesting that some portion of virus entry occurred via a pH-
independent mechanism. Similarly, baﬁlomycin only partially inhib-
ited VV entry into BSC-1 cells, although the effect was greater than in
Vero cells. Virus entry into the mouse melanoma cell line, B78H1 was
very sensitive to baﬁlomycin inhibition. In this cell type, entry was
reduced by about 90% at 12.5 nM. Baﬁlomycin exhibited a somewhat
different pattern of entry inhibition in HeLa cells. Here, vaccinia virus
entry was drastically reduced following baﬁlomycin treatment, but
required much higher concentrations of the drug. This result may
reﬂect different sensitivities of these two cell types to the effects of
baﬁlomycin. Consistent with the notion that baﬁlomycin inhibits virusentry into HeLa cells, a dramatic reduction in VV core uncoating was
observed in cells treated with baﬁlomycin (Huang et al., 2008). As in
the previous set of experiments using soluble heparin, we wanted to
ensure that baﬁlomycin did not interfere with reporter gene
expression following virus entry. To address this, we infected cells
with vSIJC-20 for 1 h prior to adding baﬁlomycin (Fig. 5B). Under these
conditions, the drug had a modest effect on virus entry into B78H1
cells and very little effect on entry into the other cell types examined
indicating that the baﬁlomycin-sensitive step of virus infection had
largely occurred during the ﬁrst hour of infection. Although we
attempted to conﬁrm the effect of baﬁlomycin on virus entry into
B78H1 cells using the immunoﬂuorescent core uncoating assay, we
were unable to obtain deﬁnitive results due to a high level of
background staining in these cells.
Inactivation of VV by low pH treatment
A number of enveloped viruses can be rapidly inactivated by
incubation at low pH. In many cases (such as with inﬂuenza virus),
such inactivation is due to irreversible triggering (conformational
change) of the viral fusion protein. Although the basis for low pH
inactivation of some viruses (ie. HSV) is unknown, this property
nevertheless provides a simple means by which to inactivate
extracellular virions to augment studies of virus entry (Highlander
et al., 1987). Because of the potential utility of such a technique, we
tested VV for low pH inactivation (Fig. 6). Virions were ﬁrst incubated
for different lengths of time at various pH levels. Treated virus samples
were then neutralized and tested for viability using the β-galactosi-
dase reporter virus entry assay. Virus was relatively insensitive to pH
levels of 5.0 and above although there was a slight loss of infectivity
compared with untreated virions (pH 7.3) perhaps due to the change
in buffer composition. At pH 4.0 and 4.5, there was an apparent
enhancement of virus infectivity similar to that originally reported
by Ichihashi (1996) and more recently by Townsley et al. (2006)
and Townsley and Moss (2007). In contrast, incubation at pH 3.5
and 3.0 resulted in a dramatic loss of infectivity. Interestingly, this
is very similar to the proﬁle of pH inactivation of HSV. Perhaps
inactivation of these two viruses at low pH occurs by a similar
mechanism. By employing this low pH inactivation step, we were
then able to examine the rate of virus entry into Vero, BSC-1, HeLa,
B78H1 and L cells.
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Because VV entry exhibited cell-type-dependent sensitivity to
baﬁlomycin (suggesting different entry pathways), we wondered
whether the kinetics of virus entry also varied with cell type. To assess
the rate of entry, virus was added to Vero, BSC-1, B78H1, HeLa and L
cells and allowed to attach for 1 h at 4 °C. In contrast to previous
reporter virus experiments, these studies were done using a multi-
plicity of infection of 0.1 pfu/cell. This was done to minimize the
possibility of saturating the cellular machinery required for virus
entry. This may be particularly important in light of the high particle
to pfu ratios typical of MV preparations (Moss, 2006). Synchronous
entry was initiated by rapidly shifting the temperature of the plates to
37 °C. Entry was allowed to proceed at 37 °C for varying lengths of
time prior to low-pH-inactivation of any remaining extracellular
virions. Following the inactivation step, infected cells were re-fed with
fresh growth medium and incubated for a total of 6 h at 37 °C. As with
other aspects of virus infection, the kinetics of VV entry were also cell-Fig. 7.Measurement of the rate of vaccinia virus entry into different cell types. vSIJC-20
was added to the indicated cells (grown in 96-well plates) and incubated for 1 h at 4 °C
to allow virus attachment, but not entry. The temperature of the culture plates was
rapidly shifted to 37 °C to initiate entry. At the indicated times following temperature
shift, the virus inoculum was removed and any remaining extracellular virions were
inactivated by addition of citrate-saline buffer (pH 3.0) for 2min. Following inactivation,
the cells were re-fed with pre-warmed DMEM–HEPES (pH 7.0). All plates were
incubated for a total of 6 h following temperature shift to 37 °C. Cells were then lysed
and assayed for β-galactosidase expression.type dependent (Fig. 7). Entry into Vero cells occurred most rapidly
and was detected within 3 min. In contrast, entry into BSC-1, B78H1,
HeLa and L cells exhibited similar kinetics and occurred more slowly
than entry into Vero cells during the initial 6–9 min of infection. Thus,
the slowest entry kinetics were observed in cells wherein virus entry
was sensitive to baﬁlomycin whereas the fastest entry correlated with
relative insensitivity to baﬁlomycin (Vero cells). Perhaps the rate of
entry into BSC-1, B78H1, HeLa and L cells reﬂects the rate of
endocytosis (leading to subsequent pH-dependent infection) while
the faster rate of entry into Vero cells reﬂects the rate of virus entry via
a different pathway/mechanism.
Discussion
As obligate intracellular parasites, viruses must ﬁrst gain access to
the interior of the host cell in order to execute their replicative cycle.
The earliest steps of virus infection are host cell attachment and entry.
We are currently studying a number of VV proteins that are present in
the virion envelope and are targets of the host protective immune
response to the virus (Aldaz-Carroll, et al., 2005a, 2005b). Antibodies
raised against some of these VV envelope proteins block virus
infection suggesting that the proteins to which they bind play roles
in attachment and/or entry.
To develop a simple, rapid and sensitive method for examining VV
entry in our laboratory, we tested the applicability of an assay based
on β-galactosidase expression in cells infected for several hours with a
reporter virus carrying the lacZ gene under the control of the p7.5
early/late VV promoter. We found that appreciable levels of β-
galactosidase expression could be detected within a few hours
following infection with the reporter virus. We further established
the sensitivity and validity of this assay by comparing the results of a
virus neutralization experiment done using the reporter virus entry
assay with a similar experiment done in parallel via the standard
plaque reduction neutralization test (PRNT). Virus neutralization was
carried out using a MAb raised against the VV L1 protein (Aldaz-
Carroll et al., 2005b). L1 has recently been shown to be required for
virion penetration of the host cell and to at least transiently associate
with members of the entry-fusion complex of MV envelope proteins
(Bisht et al., 2008; Chang and Metz, 1976; Moss, 2006). We were
encouraged by the observation that the reporter virus entry assay gave
nearly the same endpoint as the PRNT for virus neutralization by a
previously characterized monoclonal antibody.
A recently introduced assay, the detection of uncoated, cytoplas-
mic VV cores via immunoﬂuorescence microscopy, has become a
useful qualitative tool for analyzing virus entry (Locker et al., 2000;
Vanderplasschen et al., 1998). The advantage of this assay is that it
directly measures one of the earliest events in virus infection. To
further validate the results obtained using our β-galactosidase
reporter virus, we also analyzed the effect of an MV-neutralizing
antibody on the appearance of virus cores within infected cells. As
anticipated, mock-treated MV readily entered cells giving rise to
numerous intracellular cores whereas cores were only rarely detected
inside cells infected with MV that had been pre-incubated with a
neutralizing anti-L1 MAb. Despite its advantages, the core uncoating
assay is not ideal for quantitative analyses of virus entry as individual
cores must be identiﬁed within multiple microscopic ﬁelds and then
individually counted. Because of this, the core-uncoating assay is not
nearly as convenient for quantitative or high-throughput applications
as the reporter virus assay.
Many viruses are able to bind to one or more types of sulfated, cell-
surface proteoglycans (Marsh and Helenius, 2006; Olofsson and
Bergstrom, 2005). Although many studies have addressed the roles
of HSPG, CSPG and other polyanionic cell surface molecules in VV
attachment and entry (Carter et al., 2005; Chung et al., 1998; Ho et al.,
2005; Hsiao et al., 1998, 1999; Lai et al., 1990; Lin et al., 2000; Maa et
al., 1990; Moss, 2006), we re-examined the effects of soluble heparin
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published data based on plaque reduction, the β-galactosidase
reporter virus entry assay allowed us to monitor the effects of heparin
during the very early stages of virus infection. Interestingly, we
observed a marked inhibition of entry (70%) into HeLa cells by soluble
heparin whereas Carter et al. (2005) reported only a modest (27%)
inhibition. Since the previous result was obtained using a plaque
assay, we suspect that the difference reﬂects the increased sensitivity
of the β-galactosidase reporter virus assay for studies of virus entry.
The conclusion that this effect resulted from a reduction in virion
entry was conﬁrmed using the immunoﬂuorescent core uncoating
assay. In contrast to HeLa cells and in agreement with previous reports
(Carter et al., 2005; Chung et al., 1998), infection of BSC-1 and Vero
cells was relatively insensitive to heparin. These large differences in
the effect of soluble heparin on VV infection suggest that HSPG play a
variable and cell-type-dependent role as virion attachment factors.
Since the efﬁciency of VV plaque formation (plating efﬁciency) is
similar on HeLa, B78H1, Vero and BSC-1 cells (our unpublished
observations), it seems likely that other molecules present on the
surface of these cell types promote virus attachment. Consistent with
this interpretation are previously published data showing that the MV
envelope proteins D8 and A26 mediate attachment to cell surface
chondriotin sulfate and laminin, respectively (Chiu et al., 2007; Hsiao
et al., 1999). We conclude from our data that in certain cell types, virus
attachmentmediated by HSPG is very important for efﬁcient infection.
With respect to pH, there are two broad pathways by which
enveloped viruses enter cells (Marsh and Helenius, 2006). One subset
of enveloped viruses enters cells in a pH-independent manner. In this
pathway, viruses may either fuse directly with the plasma membrane
or with an endosomal membrane following internalization. Entry of
these viruses is insensitive to drugs that perturb endosomal pH.
Another subset of enveloped viruses enters by fusion with an
endosomal membrane in a pH-dependent manner. Depending upon
the virus, low pH alone may or may not be sufﬁcient to trigger
membrane fusion. In some cases, engagement of a speciﬁc receptor
and/or proteolytic activation of a virion component may be required
within the low pH compartment in order for fusion to occur. In any
case, entry of viruses requiring a low pH step is markedly reduced by
compounds that prevent endosomal acidiﬁcation.
Seemingly contradictory reports have been published on the entry
pathway used by the MV form of VV (the most abundant form
produced during its replicative cycle). Some have provided evidence of
entry via direct fusion with the plasma membrane of the host cell
(Armstrong et al., 1973; Chang and Metz, 1976; Doms et al., 1990;
Ichihashi 1996; Janeczko et al., 1987; Vanderplasschen et al., 1998)
while more recent reports have provided evidence that MV uses a pH-
dependent endosomal entry pathway in HeLa, RK-13, BSC-1 and HuTK
cells (Huang et al., 2008; Townsley et al., 2006). In light of emerging
evidence of multiple, cell-type-dependent entry pathways for herpes
simplex virus, we hypothesized that the pH-dependence of VV entry
may also exhibit cell-type-dependent differences. Using the reporter
virus entry assay, we examined the effects of baﬁlomycin A1 on VV
entry into several different cell types. Remarkably, our results varied
widely from one cell type to another. Entry into B78H1 and HeLa cells
was greatly reduced in the presence of baﬁlomycin (albeit at very
different drug concentrations) suggesting that MV entry occurs via a
pH-dependent mechanism in these cells. In contrast, MV entry into
bothAfrican greenmonkeykidneycell lines (Vero andBSC-1) exhibited
only partial sensitivity to baﬁlomycin. This could be interpreted as
evidence for the co-existence of both pH-dependent as well as pH-
independent VV entry pathways in these cells. If, indeedMV can enter
some cells via multiple pathways, it would be of particular interest to
determine whether the same or different virion proteins are required
for entry via each pathway. Similarly, it is conceivable that distinct
cellular receptors are involved in entry via pH-dependent and pH-
independent pathways. Chung et al. (2005) showed that VV entry intoBSC-40 and L cells can be blocked by depletion of cell membrane
cholesterol suggesting a role for lipid rafts in vaccinia virus entry. It will
be of interest in future experiments to determine whether this aspect
of virus entry is also cell-type-dependent.
Another aspect of virus entry that can be experimentally measured
is the rate of entry. In order to stop virus entry at deﬁned intervals, a
method of rapidly inactivating extracellular virions was needed.
Previous studies of VV entry relied on inactivation by neutralizing
antibodies (Payne and Norrby, 1978). However, virus neutralization
with antibodies may not occur quickly enough to allow sensitive
measurements of entry kinetics. Since herpes simplex virus has been
shown to be rapidly inactivated by treatment at pH 3.0 (Highlander et
al., 1987), we tested the effect of low pH treatment on MV infectivity.
Like HSV, VV was inactivated following a brief incubation at pH 3.0.
Using the β-galactosidase reporter virus entry assay coupled with a
low pH inactivation step, we examined the kinetics of MV entry into
several cell types. Although only modest differences were observed in
the rates of virus entry into different cell types, we did note a short,
but reproducible lag in entry into BSC-1, B78H1, HeLa and L cells. This
entry lag was diminished or absent in Vero cells. The correlation of
delayed entry with increased baﬁlomycin sensitivity (in BSC-1, B78H1,
HeLa and L cells) and faster entry with reduced baﬁlomycin sensitivity
(Vero cells) suggested to us that perhaps slower entry reﬂects the rate
at which virions are endocytosed (leading to subsequent pH-
dependent infection) while faster entry reﬂects the rate of entry via
a different, pH-independent pathway.
We recently reported the results of a series of experiments
evaluating the efﬁcacy of a subunit vaccine against infection with VV
(Fogg et al., 2004, 2007; Xiao et al., 2007). These studies showed that
immunization of mice with various combinations of puriﬁed, recom-
binant A33, B5, L1 and A27 afforded protection froma lethal dose of VV
comparable to the protection provided by immunization with live VV
(Dryvax). Interestingly, a subunit vaccine consisting of all or a subset of
these VV proteins also protected animals against heterologous
orthopoxvirus challenges. To wit, vaccinated mice were completely
protected against a lethal ectromelia virus challenge (Xiao et al., 2007)
and vaccinated monkeys were protected against a lethal monkeypox
challenge (Fogg et al., 2007). Notwithstanding the effectiveness of this
subunit vaccine in monkeys, use of the replication-deﬁcient VV strain
MVA, afforded more complete protection against the appearance of
lesions associated with monkeypox challenge (Earl et al., 2004). One
explanation for this difference is that there may be additional,
potentially important viral targets of the host protective immune
response to VV and, by extension, monkeypox virus and variola virus.
Based on the studies reported here showing that some important
characteristics of VV entry differ depending upon the host cell, we
suspect that theremay be differences in the importance of certain viral
proteins for entry into cells of different tissues or host species. If this is
true, the targets of virus-neutralizing antibodies may depend, at least
to some extent, upon the cell type or species being infected. Future
subunit vaccine protein formulations may be improved based upon
studies of VV entry into relevant human tissues.
Materials and methods
Cells and virus
BSC-1, B78H1, Vero, HeLa, L, Sog9 and gro2c cells were grown in
DMEM supplemented with 10% fetal bovine serum and penicillin–
streptomycin (Invitrogen). The vaccinia virus used throughout these
studies was vSIJC-20, a β-galactosidase reporter virus constructed in
the background of strain WR (a gift of Stuart N. Isaacs, University of
Pennsylvania). This virus was constructed, as described elsewhere
(Girgis et al., 2008), by targeted recombination of the lacZ ORF under
transcriptional control of the vaccinia early/late p7.5 promoter into the
thymidine kinase locus of the vaccinia genome. A His-tagged form of
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the tk locus of vSIJC-20. Reporter virus stocks were propagated in BSC-
1 cells. For MV stock preparation, cells were infected at a multiplicity
of 0.05 pfu/cell and incubated at 37 °C until cytopathic effect was
complete (3–4 days). Infected cell cultures were frozen at −80 °C and
then thawed completely. This freeze–thaw cycle was repeated 2 times
to effect release of MV particles. The culture supernatant was cleared
of debris by centrifugation at 2000 ×g for 30 min at 4 °C. MV stocks
prepared in this way were stored at −80 °C and typically had titers
around 107 pfu/mL. Gradient-puriﬁed virus was obtained by pelleting
virus particles from clariﬁed tissue culture supernatant through a 36%
sucrose (w/v) cushion (in 10 mM Tris (pH 9.0)) for 2 h at 25,000 ×g.
Pelleted virus was then resuspended in 10 mM Tris (pH 9.0), sonicated
and loaded atop a stepwise gradient of 60 %, 36 % and 15% sucrose
(prepared in 10 mM Tris (pH 9.0)). Gradients were centrifuged at
55,000 ×g for 2 h and banded virus was collected via side puncture of
the tube. Recovered virus was then further concentrated by pelleting
through a cushion of 36% sucrose for 2 h at 5000 ×g. The resulting
pellet was resuspended in 1 mL of PBS, sonicated and stored at −80 °C.
Virus titers were routinely determined by plaque assay on BSC-1 cells.
However, we have noted in separate experiments that similar titers
(less than 2-fold differences) are obtained upon plaque assay using
B78H1, Vero and HeLa cells. Plaques were visualized using immuno-
peroxidase staining of infected cell monolayers. Infected cell mono-
layers (24–48 h post-infection) were ﬁxed for 30 min in methanol:
acetone (2:1, vol/vol) and allowed to dry completely. Fixedmonolayers
were then re-hydrated in PBS for 5 min and blocked in PBS containing
2% BSA (PBS-BSA). Monolayers were then incubated for 1 hwith rabbit
polyclonal antisera raised against B5 and L1 (Aldaz-Carroll, et al.,
2005a, 2005b) diluted 1:1000 in PBS-BSA. Monolayers were then
washed 3 times with PBS and incubated for 1 h. in Protein A-HRP
(Amersham) conjugate diluted 1:1000 in PBS-BSA. Monolayers were
then washed 3 times with PBS and incubated in PBS containing
100mg/mL 4-chloro-1-naphthol and 0.1% (vol/vol) hydrogen peroxide
until the development of color (typically 10–30 min).
Antibodies
Rabbit polyclonal antiserum R236 was generated by immunizing a
rabbit with 2 synthetic peptidesmimicking portions of the vaccinia A4
core polypeptide (strain WR, GenBank accession number:
NC_006998). The A4 sequences withinin the peptides were:
YYSEEKDPDTKKDEAI and SKFNKDQKTTTPPSTQP. Synthetic peptides
(Biosynthesis, Lewisville, TX) were coupled to keyhole limpet
hemocyanin (KLH) for immunization of rabbits. Monoclonal antibody
VMC-2 was obtained following immunization of a mouse with a
recombinant form of vaccinia L1 (Aldaz-Carroll et al., 2005b).
Immunoﬂuorescence microscopy of intracellular VV cores
HeLa cells were seeded onto glass coverslips and incubated for 20 h
at 37 °C in a humidiﬁed CO2 incubator. Prior to the addition of virus,
cells were chilled on ice for 30 min. For studies on the effects of a
neutralizing MAb, virus was pre-incubated for 1 h at 37 °C in the
presence of various concentrations of MAb VMC-2 (Aldaz-Carroll et al.,
2005b), chilled on ice and added to cells. For studies on the effects of
soluble heparin, virus was pre-incubated for 1 h at 37 °C in the
presence of various concentrations of heparin (Sigma), chilled on ice
and added to cells. After 1 h on ice, the plates were warmed by
ﬂoatation in a 37 °C water bath for 10 min. The plates were then
transferred to a 37 °C, humidiﬁed CO2 incubator for 90 min. The plates
were then chilled on ice, washed 3 timeswith ice-cold PBS and ﬁxed in
ice-cold 3% paraformaldehyde. All subsequent steps were performed
at room temperature. Cells were washed 3 times in PBS, quenched
10 min in 50 mM NH4Cl, permeabilized using 0.1% saponin (in PBS)
and blocked for a minimum of 1 h in blocking solution (PBS containing10% goat serum). Cells were then incubated 45 min in blocking
solution containing 0.25 μg/mL R236 IgG, washed with PBS and
further incubated for 30 min in blocking solution containing
ﬂuorescent-tagged antibody (Alexa-488, Molecular Probes) and
wheat-germ agglutinin (Alexa 594, Molecular Probes) each diluted
1:1000. Coverslips were then washed 3 times in PBS, once in distilled
water and mounted on microscope slides using ProLong Antifade
mounting solution (Molecular Probes).
Virus neutralization assay
IgG was prepared from ascitic ﬂuid containing MAb VMC-2 via
protein G sepharose chromatography as peviously described (Aldaz-
Carroll et al., 2005b). IgG was diluted in DMEM containing 10% heat-
inactivated FBS and thenmixed with an equal volume of vaccinia virus
(vSIJC-20). The virus-IgGmixturewas incubated for 1 h at 37 °C, added
to HeLa cells and incubated at 37 °C for 72 h (plaque assay) or for 6 h
(for reporter gene expression). Plaques were visualized by staining
infected monolayers with 0.1% crystal violet. β-galactosidase expres-
sion following reporter virus infection was determined as previously
described (Whitbeck et al., 1997). Brieﬂy, virus-infected and control
(uninfected) cells were lysed by addition of an equal volume of PBS
containing 1% NP-40 (ﬁnal concentration of NP-40 in each well is
0.5%). Cell lysates were then mixed in a separate 96-well ELISA plate
with the β-galactosidase substrate, ONPG. Plates were read in a BioTek
Synergy 2 plate reader at 570 nm. Data were collected at 5-minute
intervals over 50 min. The data shown reﬂect the rate of substrate
conversion over time.
Heparin inhibition of vaccinia virus entry
vSIJC-20 was incubated in the presence of soluble heparin (various
concentrations) for 1 h at 37 °C. Virus and heparinwere then added to
cells grown in 96-well plates and incubated for 6 h at 37 °C in a
humidiﬁed CO2 incubator. Cells were then lysed by addition of an
equal volume of PBS containing 1% NP-40. β-galactosidase activity was
determined as described above.
Baﬁlomycin inhibition of vaccinia virus entry
Cells grown in 96-well plates were incubated for 1 h at 37 °C with
various concentrations of baﬁlomycin A1 (Sigma) diluted in growth
medium containing 0.1% DMSO. Medium containing baﬁlomycin A1
was removed and cells were then infected with vaccinia virus at 1 pfu/
cell and incubated at 37 °C for 6 h. Cells were then lysed by addition of
an equal volume of PBS containing 1% NP-40. β-galactosidase activity
was determined as described above.
Low pH inactivation of vaccinia virus
Gradient-puriﬁed virus was diluted and divided into multiple
aliquots of 10 μL (each aliquot contained 1×106 pfu). Aliquots were
then shifted to different pH levels by adding 90 μL of either PBS (pH
7.3) or citrate-saline buffers (pH 6.0, 5.0, 4.5, 4.0, 3.5 and 3.0) and
incubated at 37 °C for various times (Highlander et al., 1987).
Following low pH treatment, samples were neutralized by adding
0.9 mL cell growthmedium containing 40 mMHEPES (pH 7) and used
to inoculate BSC-1 cells in a 96-well plate. Plates were incubated for
6 h at 37 °C in a humidiﬁed CO2 incubator. Cells were then lysed by
addition of an equal volume of PBS containing 1% NP-40. β-
galactosidase activity was determined as described above.
Vaccinia virus penetration assay
Cells grown in 96-well plates were incubated for 1 h at 4 °C with
vaccinia virus (0.1 pfu/cell) to allow virus attachment, but not entry.
391J.C. Whitbeck et al. / Virology 385 (2009) 383–391Plates were then rapidly shifted to 37 °C by ﬂoating atop a 37 °C water
bath for 3 min. Virus-containing mediumwas then removed and cells
were incubated in pre-warmed (37 °C) citrate-saline buffer (pH 3) for
2 min at 37 °C. Citrate-saline buffer was then removed and cells were
re-fed with pre-warmed growth medium supplemented with 40 mM
HEPES (pH 7). Plates were incubated for a total of 6 h at 37 °C in a
humidiﬁed CO2 incubator. Cells were then lysed by addition of an
equal volume of PBS containing 1% NP-40. β-galactosidase activity was
determined as described above.
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